Atara

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Retrieved on: 
Monday, December 11, 2023

Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.

Key Points: 
  • Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.
  • The data will be presented in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place December 9-12, 2023, in San Diego.
  • ATA3431 also incorporates the clinically validated 1XX costimulatory domain that enhances stemness and modulates exhaustion to extend functional persistence.
  • Compared to an autologous CD20/CD19 CAR-T benchmark, the ATA3431 preclinical data demonstrate potent antitumor activity, long-term persistence, and superior tumor growth inhibition.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, July 28, 2022

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Atara issued a press release on July 12, 2022, updating the market on its preliminary analysis phase 2 EMBOLD study for product candidate ATA188.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc.

Retrieved on: 
Wednesday, July 27, 2022

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.

Key Points: 
  • New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .
  • Then, on February 28, 2022, Atara issued a press release attached to their Form 8-K, providing an update on ATA188.

Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

Retrieved on: 
Wednesday, March 23, 2022

Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022.

Key Points: 
  • Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022.
  • Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in July.
  • View the full release here: https://www.businesswire.com/news/home/20220323005304/en/
    Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022.
  • Thereafter, Dr. Baynes joined Amgen, Inc., where he became Vice President of Global Development and head of the hematology/oncology development team.

CSafe Global Announces Appointment of New Board Member

Retrieved on: 
Wednesday, February 23, 2022

DAYTON, Ohio, Feb. 23, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled container solutions for the transport of life-enhancing pharmaceuticals, announced today that Joe Newell has been appointed to the company's board of directors. With this appointment the Board will comprise 9 directors.

Key Points: 
  • With this appointment the Board will comprise 9 directors.
  • "We are pleased to welcome Joe to the CSafe board," said CSafe CEO and board member, Patrick Schafer.
  • "Joe is a pivotal addition to our board," said Bill Mitchell, CSafe Chairman of the Board and Executive in Residence for Frazier Healthcare Partners.
  • "I am extremely excited to join the CSafe Global board and work with a seasoned and highly successful executive team," said Newell.

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, August 2, 2021

These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of August 2, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of August 2, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
  • Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

Retrieved on: 
Monday, August 2, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.
  • Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Companys financial results and provide a corporate update.
  • Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13720150.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

Retrieved on: 
Monday, July 12, 2021

BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors.

Key Points: 
  • BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors.
  • Commenting on his appointment, Mr. Koppikar said, "I am honored to join Flexions Board of Directors at this exciting point in the companys evolution.
  • Mr. Koppikar joined Atara Biotherapeutics in June 2018, and oversees Finance, Information Technology, and Investor Relations.
  • Prior to his tenure with Atara, Mr. Koppikar held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance.

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, July 2, 2021

These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of July 1, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of July 1, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
  • Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Seeking Alpha Speaks with Samsara Luggage CEO About Increasing Revenue, Future Goals and Uplisting

Retrieved on: 
Wednesday, June 16, 2021

"I was thrilled to speak with Seeking Alpha about the unique and fantastic opportunities ahead," said Atara Dzikowski.

Key Points: 
  • "I was thrilled to speak with Seeking Alpha about the unique and fantastic opportunities ahead," said Atara Dzikowski.
  • "We are constantly developing new technology and products designed to transform the future of travel.
  • Samsara's Next Gen smart carry-on suitcase is expected to launch in the coming months, as travel continues to resume activity.
  • Samsara Luggage, Inc. is a global smart luggage and smart travel brand with a deep belief in creating a world where travel isn't a hassle, but rather an effortless experience.